Skip to main content
. 2019 Oct 1;8(10):1565. doi: 10.3390/jcm8101565

Table 4.

Haploidentical hematopoietic stem cell transplantation (HSCT) in adults with SCD.

Conditioning Regimen GVHD Prophylaxis N Age
(years)		 Graft
Source		 Event-free
Survival		 Overall
Survival		 aGVHD
(≥grade2)		 cGVHD
(≥moderate)		 Reference
Fludarabine (150 mg/m2)
Cy (29 mg/kg)
ATG (4.5 mg/kg)
Total body irradiation (200 cGy)

  • Cy 50 mg/kg/day on day +3, 4

  • MMF until day +35

  • Tacrolimus or Sirolimus

 14 15–42 Bone
Marrow		 57% 100% 0% 0% [64]
Alemtuzumab (1 mg/kg)
Total body irradiation (400 cGy)

  • Cy 50 mg/kg/day on day +3, 4

  • Sirolimus

 12 20–56 PBSC 50% 92% 0% 0% [68]
Fludarabine (150 mg/m2)
Cy (29 mg/kg)
ATG (4.5 mg/kg)
Total body irradiation (300 cGy)

  • Cy 50 mg/kg/day on day +3, 4

  • MMF until day +35

  • Sirolimus

 8 20–38 PBSC 75% 88% 25% 13% [65]
Pre-HSCT Immunosuppression:
Fludarabine (200 mg/m2)
Dexamethasone (125 mg/m2)
Conditioning:
Fludarabine (210 mg/m2)
Busulfan (520 mg/m2)
ATG (4.5 mg/kg)

  • Cy 50 mg/kg/day on day +3, 4

  • MMF until day +28

  • Tacrolimus

 4 12–24 Bone Marrow
(n = 3)
PBSC
(n = 1)		 100% 100% 0% 0% [67]
Fludarabine (150 mg/m2)
Cy (29 mg/kg)
Thiotepa (10 mg/kg)
ATG (4.5 mg/kg)
Total body irradiation (300 cGy)

  • Cy 50 mg/kg/day on day +3, 4

  • MMF until day +35

  • Sirolimus

 15 7–40 Bone Marrow 93% 100% 13% 0% [66]